Overview of Kybella (Deoxycholic Acid Injection) as a Fat Resorption Product for Submental Fat

Area of Science:

• Cosmetic Medicine
• Dermatology
• Aesthetic Surgery

Background:

• Growing interest in addressing submental fat (SMF) driven by increased focus on facial aesthetics.
• Prevalence of social media and video calls heightens emphasis on facial image.
• Traditional invasive procedures like liposuction and neck lifts remain options for SMF reduction.

Purpose of the Study:

• To introduce ATX-101 (Kybella) as a novel, minimally invasive treatment for submental fat.
• To highlight the safety and efficacy of this new injectable treatment.

Main Methods:

• Review of minimally invasive cosmetic procedures.
• Focus on the development and approval of injectable treatments for submental fat.
• Identification of ATX-101 as the first FDA-approved injectable for SMF.

Main Results:

• ATX-101 (Kybella) is the first single Food and Drug Administration-approved injectable treatment for submental fat.
• The injectable offers a safe and effective alternative to invasive procedures.
• Minimally invasive methods are gaining traction in cosmetic medicine.

Conclusions:

• ATX-101 (Kybella) represents a significant advancement in the minimally invasive treatment of submental fat.
• The injectable provides a safe and effective option for patients seeking to reduce submental fat.
• The trend towards minimally invasive cosmetic procedures is evident in the development of treatments like Kybella.